News

• FDA approves generic teriparatide and levetiracetam
• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs

Research

• Japan’s drug shortage crisis: challenges and policy solutions
• Saudi FDA drug approvals and GMP inspections: trend analysis
• Generic medications in the Lebanese community: understanding and public perception
• Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study

General

• Generic drug growth in Brazil and Venezuela
• EMA launches European shortages monitoring platform to tackle persistent medicine shortages
• Market penetration of generic drugs in Mexico and Brazil
• FDA releases one-year progress report for the Generic Drug Cluster

News

• EMA recommends approval for three biosimilars: Jubereq, Osvyrti, and Qoyvolma
• FDA biosimilar approvals in March 2025: Bomyntra, Conexxence, and Omlyclo
• Canada approves pegfilgrastim biosimilar Pexegra
• Insulin aspart and denosumab biosimilars approved in US

Research

• How the WHO is expanding access to biosimilars
• Optimizing costs with biosimilars: Brazil's case
• Biosimilars in low- and middle-income countries
• Positive safety and efficacy primary endpoint results for AVT05 (golimumab proposed biosimilar)

General

• Stelara biosimilars enter US market with 85% discount in 2025
• Biosimilars approved in Canada
• IFPMA publishes position on pharmacy-mediated substitution for biosimilars
• The ustekinumab shift: biosimilars displace Stelara’s market leadership

• Latin American Forum
• Non‐Biological Complex Drugs
• Country Focus

• Guidelines
• Policies & Legislation
• Reports

• Conferences
• Sponsored Articles
• Sponsored Links